Corrigendum to “Efficient Restoration of the Dystrophin Gene Reading Frame and Protein Structure in DMD Myoblasts Using the CinDel Method” (Molecular Therapy - Nucleic Acids (2016) 5 (S2162253117300148), (10.1038/mtna.2015.58));Efficient Restoration of the Dystrophin Gene Reading Frame and Protein Structure in DMD Myoblasts Using the CinDel Method

Molecular Therapy Nucleic Acids

Volumn 5, Issue , 2016, Pages e283-

  Iyombe Engembe, Jean Paul ^a,b   Ouellet, Dominique L ^a,b   Barbeau, Xavier ^c   Rousseau, Joël ^a,b   Chapdelaine, Pierre ^a,b   Lagüe, Patrick ^c   Tremblay, Jacques P ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c UNIVERSITÉ LAVAL   (Canada)

Author keywords

Cas9; CRISPR; DMD gene; Duchenne muscular dystrophy; dystrophin; gene therapy; gRNA

Indexed keywords

DYSTROPHIN; GENOMIC DNA; GUIDE RNA;

ALPHA HELIX; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; CRISPR INDUCED DELETION GENE THERAPY; DUCHENNE MUSCULAR DYSTROPHY; ELECTROPORATION; EXON; EXON SKIPPING; GENE DELETION; GENE EDITING; GENE EXPRESSION; GENE FUSION; GENE INSERTION; GENE TARGETING; GENE THERAPY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INDEL MUTATION; INTRON; MOUSE; MYOBLAST; MYOTUBE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN STRUCTURE; READING FRAME; SPECTRIN LIKE REPEAT; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

EID: 85015681287     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2016.30     Document Type: Erratum

References (68)

1. 1 Engel, A, Banker, BQ, Myology: Basic and Clinical, 1986, McGraw-Hill, New York.
2. 2 Rybakova, IN, Patel, JR, Ervasti, JM, The dystrophin complex forms a mechanically strong link between the sarcolemma and costameric actin. J Cell Biol 150 (2000), 1209–1214.
3. 3 Hoffman, EP, Brown, RH Jr, Kunkel, LM, Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51 (1987), 919–928.
4. 4 Hoffman, EP, Brown, RH, Kunkel, LM, Dystrophin: the protein product of the Duchene muscular dystrophy locus. 1987. Biotechnology 24 (1992), 457–466.
5. 5 Bladen, CL, Salgado, D, Monges, S, Foncuberta, ME, Kekou, K, Kosma, K, et al. The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations. Hum Mutat 36 (2015), 395–402.
6. 6 Koenig, M, Beggs, AH, Moyer, M, Scherpf, S, Heindrich, K, Bettecken, T, et al. The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am J Hum Genet 45 (1989), 498–506.
7. 7 Hoffman, EP, Genotype/phenotype correlations in Duchenne/Becker dystrophy. Mol Cell Biol Hum Dis Ser 3 (1993), 12–36.
8. 8 Emery, AE, The muscular dystrophies. Lancet 359 (2002), 687–695.
9. 9 Duan, D, Duchenne muscular dystrophy gene therapy: lost in translation?. Res Rep Biol 2011 (2011), 31–42.
10. 10 Goyenvalle, A, Seto, JT, Davies, KE, Chamberlain, J, Therapeutic approaches to muscular dystrophy. Hum Mol Genet 20 (2011), R69–R78.
11. 11 Konieczny, P, Swiderski, K, Chamberlain, JS, Gene and cell-mediated therapies for muscular dystrophy. Muscle Nerve 47 (2013), 649–663.
12. 12 Mendell, JR, Rodino-Klapac, L, Sahenk, Z, Malik, V, Kaspar, BK, Walker, CM, et al. Gene therapy for muscular dystrophy: lessons learned and path forward. Neurosci Lett 527 (2012), 90–99.
13. 13 Verhaart, IE, Aartsma-Rus, A, Gene therapy for Duchenne muscular dystrophy. Curr Opin Neurol 25 (2012), 588–596.
14. 14 Monaco, AP, Neve, RL, Colletti-Feener, C, Bertelson, CJ, Kurnit, DM, Kunkel, LM, Isolation of candidate cDNAs for portions of the Duchenne muscular dystrophy gene. Nature 323 (1986), 646–650.
15. 15 Kunkel, LM, Hejtmancik, JF, Caskey, CT, Speer, A, Monaco, AP, Middlesworth, W, et al. Analysis of deletions in DNA from patients with Becker and Duchenne muscular dystrophy. Nature 322 (1986), 73–77.
16. 16 Gregorevic, P, Blankinship, MJ, Allen, JM, Crawford, RW, Meuse, L, Miller, DG, et al. Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat Med 10 (2004), 828–834.
17. 17 Gregorevic, P, Allen, JM, Minami, E, Blankinship, MJ, Haraguchi, M, Meuse, L, et al. rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat Med 12 (2006), 787–789.
18. 18 Wang, Z, Kuhr, CS, Allen, JM, Blankinship, M, Gregorevic, P, Chamberlain, JS, et al. Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. Mol Ther 15 (2007), 1160–1166.
19. 19 Qiao, C, Koo, T, Li, J, Xiao, X, Dickson, JG, Gene therapy in skeletal muscle mediated by adeno-associated virus vectors. Methods Mol Biol 807 (2011), 119–140.
20. 20 Aartsma-Rus, A, Overview on DMD exon skipping. Methods Mol Biol 867 (2012), 97–116.
21. 21 Aartsma-Rus, A, van Ommen, GJ, Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications. RNA 13 (2007), 1609–1624.
22. 22 Aartsma-Rus, A, van Ommen, GJ, Less is more: therapeutic exon skipping for Duchenne muscular dystrophy. Lancet Neurol 8 (2009), 873–875.
23. 23 Bremmer-Bout, M, Aartsma-Rus, A, de Meijer, EJ, Kaman, WE, Janson, AA, Vossen, RH, et al. Targeted exon skipping in transgenic hDMD mice: a model for direct preclinical screening of human-specific antisense oligonucleotides. Mol Ther 10 (2004), 232–240.
24. 24 Dunckley, MG, Manoharan, M, Villiet, P, Eperon, IC, Dickson, G, Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides. Hum Mol Genet 7 (1998), 1083–1090.
25. 25 Lu, QL, Mann, CJ, Lou, F, Bou-Gharios, G, Morris, GE, Xue, SA, et al. Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nat Med 9 (2003), 1009–1014.
26. 26 Mann, CJ, Honeyman, K, McClorey, G, Fletcher, S, Wilton, SD, Improved antisense oligonucleotide induced exon skipping in the mdx mouse model of muscular dystrophy. J Gene Med 4 (2002), 644–654.
27. 27 Takeshima, Y, Yagi, M, Wada, H, Ishibashi, K, Nishiyama, A, Kakumoto, M, et al. Intravenous infusion of an antisense oligonucleotide results in exon skipping in muscle dystrophin mRNA of Duchenne muscular dystrophy. Pediatr Res 59 (2006), 690–694.
28. 28 van Deutekom, JC, Janson, AA, Ginjaar, IB, Frankhuizen, WS, Aartsma-Rus, A, Bremmer-Bout, M, et al. Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 357 (2007), 2677–2686.
29. 29 Kinali, M, Arechavala-Gomeza, V, Feng, L, Cirak, S, Hunt, D, Adkin, C, et al. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol 8 (2009), 918–928.
30. 30 Lu, QL, Cirak, S, Partridge, T, What can we learn from clinical trials of exon skipping for DMD?. Mol Ther Nucleic Acids, 3, 2014, e152.
31. 31 Ousterout, DG, Kabadi, AM, Thakore, PI, Perez-Pinera, P, Brown, MT, Majoros, WH, et al. Correction of dystrophin expression in cells from Duchenne muscular dystrophy patients through genomic excision of exon 51 by zinc finger nucleases. Mol Ther 23 (2015), 523–532.
32. 32 Rousseau, J, Chapdelaine, P, Boisvert, S, Almeida, LP, Corbeil, J, Montpetit, A, et al. Endonucleases: tools to correct the dystrophin gene. J Gene Med 13 (2011), 522–537.
33. 33 Li, HL, Fujimoto, N, Sasakawa, N, Shirai, S, Ohkame, T, Sakuma, T, et al. Precise correction of the dystrophin gene in duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9. Stem Cell Reports 4 (2015), 143–154.
34. 34 Ousterout, DG, Perez-Pinera, P, Thakore, PI, Kabadi, AM, Brown, MT, Qin, X, et al. Reading frame correction by targeted genome editing restores dystrophin expression in cells from Duchenne muscular dystrophy patients. Mol Ther 21 (2013), 1718–1726.
35. 35 Long, C, McAnally, JR, Shelton, JM, Mireault, AA, Bassel-Duby, R, Olson, EN, Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA. Science 345 (2014), 1184–1188.
36. 36 Nakamura, K, Fujii, W, Tsuboi, M, Tanihata, J, Teramoto, N, Takeuchi, S, et al. Generation of muscular dystrophy model rats with a CRISPR/Cas system. Sci Rep, 4, 2014, 5635.
37. 37 Ousterout, DG, Kabadi, AM, Thakore, PI, Majoros, WH, Reddy, TE, Gersbach, CA, Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy. Nat Commun, 6, 2015, 6244.
38. 38 Ran, FA, Cong, L, Yan, WX, Scott, DA, Gootenberg, JS, Kriz, AJ, et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature 520 (2015), 186–191.
39. 39 Cong, L, Ran, FA, Cox, D, Lin, S, Barretto, R, Habib, N, et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339 (2013), 819–823.
40. 40 Jinek, M, East, A, Cheng, A, Lin, S, Ma, E, Doudna, J, RNA-programmed genome editing in human cells. Elife, 2, 2013, e00471.
41. 41 Sander, JD, Joung, JK, CRISPR-Cas systems for editing, regulating and targeting genomes. Nat Biotechnol 32 (2014), 347–355.
42. 42 Mali, P, Yang, L, Esvelt, KM, Aach, J, Guell, M, DiCarlo, JE, et al. RNA-guided human genome engineering via Cas9. Science 339 (2013), 823–826.
43. 43 Cho, SW, Kim, S, Kim, JM, Kim, JS, Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat Biotechnol 31 (2013), 230–232.
44. 44 Doudna, JA, Charpentier, E, Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science, 346, 2014, 1258096.
45. 45 Zheng, Q, Cai, X, Tan, MH, Schaffert, S, Arnold, CP, Gong, X, et al. Precise gene deletion and replacement using the CRISPR/Cas9 system in human cells. Biotechniques 57 (2014), 115–124.
46. 46 Deltcheva, E, Chylinski, K, Sharma, CM, Gonzales, K, Chao, Y, Pirzada, ZA, et al. CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature 471 (2011), 602–607.
47. 47 Marraffini, LA, Sontheimer, EJ, CRISPR interference: RNA-directed adaptive immunity in bacteria and archaea. Nat Rev Genet 11 (2010), 181–190.
48. 48 Jinek, M, Chylinski, K, Fonfara, I, Hauer, M, Doudna, JA, Charpentier, E, A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337 (2012), 816–821.
49. 49 Nicolas, A, Lucchetti-Miganeh, C, Yaou, RB, Kaplan, JC, Chelly, J, Leturcq, F, et al. Assessment of the structural and functional impact of in-frame mutations of the DMD gene, using the tools included in the eDystrophin online database. Orphanet J Rare Dis, 7, 2012, 45.
50. 50 Canver, MC, Bauer, DE, Dass, A, Yien, YY, Chung, J, Masuda, T, et al. Characterization of genomic deletion efficiency mediated by clustered regularly interspaced palindromic repeats (CRISPR)/Cas9 nuclease system in mammalian cells. J Biol Chem 289 (2014), 21312–21324.
51. 51 Aartsma-Rus, A, Kaman, WE, Weij, R, den Dunnen, JT, van Ommen, GJ, van Deutekom, JC, Exploring the frontiers of therapeutic exon skipping for Duchenne muscular dystrophy by double targeting within one or multiple exons. Mol Ther 14 (2006), 401–407.
52. 52 Béroud, C, Tuffery-Giraud, S, Matsuo, M, Hamroun, D, Humbertclaude, V, Monnier, N, et al. Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy. Hum Mutat 28 (2007), 196–202.
53. 53 Xu, L, Park, KH, Zhao, L, Xu, J, El Refaey, M, Gao, Y, et al. CRISPR-mediated genome editing restores dystrophin expression and function in mdx mice. Mol Ther, 2015 (epub ahead of print).
54. 54 Skuk, D, Tremblay, JP, Clarifying misconceptions about myoblast transplantation in myology. Mol Ther 22 (2014), 897–898.
55. 55 Skuk, D, Tremblay, JP, Intramuscular cell transplantation as a potential treatment of myopathies: clinical and preclinical relevant data. Expert Opin Biol Ther 11 (2011), 359–374.
56. 56 Bruusgaard, JC, Liestøl, K, Ekmark, M, Kollstad, K, Gundersen, K, Number and spatial distribution of nuclei in the muscle fibres of normal mice studied in vivo. J Physiol 551 (2003), 467–478.
57. 57 Kinoshita, I, Vilquin, JT, Asselin, I, Chamberlain, J, Tremblay, JP, Transplantation of myoblasts from a transgenic mouse overexpressing dystrophin prduced only a relatively small increase of dystrophin-positive membrane. Muscle Nerve 21 (1998), 91–103.
58. 58 Pavlath, GK, Rich, K, Webster, SG, Blau, HM, Localization of muscle gene products in nuclear domains. Nature 337 (1989), 570–573.
59. 59 Slaymaker, IM, Gao, L, Zetsche, B, Scott, DA, Yan, WX, Zhang, F, Rationally engineered Cas9 nucleases with improved specificity. Science, 2015 (epub ahead of print).
60. 60 Tsai, SQ, Zheng, Z, Nguyen, NT, Liebers, M, Topkar, VV, Thapar, V, et al. GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat Biotechnol 33 (2015), 187–197.
61. 61 Wang, X, Wang, Y, Wu, X, Wang, J, Wang, Y, Qiu, Z, et al. Unbiased detection of off-target cleavage by CRISPR-Cas9 and TALENs using integrase-defective lentiviral vectors. Nat Biotechnol 33 (2015), 175–178.
62. 62 Friedland, AE, Baral, R, Singhal, P, Loveluck, K, Shen, S, Sanchez, M, et al. Characterization of Staphylococcus aureus Cas9: a smaller Cas9 for all-in-one adeno-associated virus delivery and paired nickase applications. Genome Biol, 16, 2015, 257.
63. 63 Ran, FA, Hsu, PD, Wright, J, Agarwala, V, Scott, DA, Zhang, F, Genome engineering using the CRISPR-Cas9 system. Nat Protoc 8 (2013), 2281–2308.
64. 64 Zhang, Y, Skolnick, J, TM-align: a protein structure alignment algorithm based on the TM-score. Nucleic Acids Res 33 (2005), 2302–2309.
65. 65 Yang, J, Yan, R, Roy, A, Xu, D, Poisson, J, Zhang, Y, The I-TASSER Suite: protein structure and function prediction. Nat Methods 12 (2015), 7–8.
66. 66 Yang, J, Zhang, Y, I-TASSER server: new development for protein structure and function predictions. Nucleic Acids Res 43 (2015), W174–W181.
67. 67 Roy, A, Kucukural, A, Zhang, Y, I-TASSER: a unified platform for automated protein structure and function prediction. Nat Protoc 5 (2010), 725–738.
68. 68 Zhang, Y, I-TASSER server for protein 3D structure prediction. BMC Bioinformatics, 9, 2008, 40.